Effect of Dapagliflozin (Forxiga) on hepatic lipid content and microbiota in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes mellitus
Latest Information Update: 10 Jul 2018
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 30 Jun 2018 Status changed from not yet recruiting to recruiting.
- 28 Dec 2017 New trial record